Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E
- PMID: 8592548
- DOI: 10.1056/NEJM199603213341202
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E
Abstract
Background: Variants of the apolipoprotein E allele appear to account for most cases of late-onset Alzheimer's disease, and persons with two copies of the epsilon 4 allele appear to have an especially high risk of dementia. Positron-emission tomography (PET) has identified specific regions of the brain in which the rate of glucose metabolism declines progressively in patients with probable Alzheimer's disease. We used PET to investigate whether these same regions of the brain are affected in subjects homozygous for the epsilon 4 allele before the onset of cognitive impairment.
Methods: Apolipoprotein E genotypes were established in 235 volunteers 50 to 65 years of age who reported a family history of probable Alzheimer's disease. Neurologic and psychiatric evaluations, a battery of neuropsychological tests, magnetic resonance imaging, and PET were performed in 11 epsilon 4 homozygotes and 22 controls without the epsilon 4 allele who were matched for sex, age, and level of education. An automated method was used to generate an aggregate surface-projection map that compared regional rates of glucose metabolism in the two groups.
Results: The epsilon 4 homozygotes were cognitively normal. They had significantly reduced rates of glucose metabolism in the same posterior cingulate, parietal, temporal, and prefrontal regions as in previously studied patients with probable Alzheimer's disease. They also had reduced rates of glucose metabolism in additional prefrontal regions, which may be preferentially affected during normal aging.
Conclusions: In late middle age, cognitively normal subjects who are homozygous for the epsilon 4 allele for apolipoprotein E have reduced glucose metabolism in the same regions of the brain as in patients with probable Alzheimer's disease. These findings provide preclinical evidence that the presence of the epsilon 4 allele is a risk factor for Alzheimer's disease. PET may offer a relatively rapid way of testing future treatments to prevent Alzheimer's disease.
Comment in
-
Second cancers after Hodgkin's disease in childhood.N Engl J Med. 1996 Mar 21;334(12):792-4. doi: 10.1056/NEJM199603213341210. N Engl J Med. 1996. PMID: 8592556 No abstract available.
-
Positron-emission tomography and Alzheimer's disease.N Engl J Med. 1996 Jul 18;335(3):207-8. N Engl J Med. 1996. PMID: 8657229 No abstract available.
Similar articles
-
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9. doi: 10.1073/pnas.2635903100. Epub 2003 Dec 19. Proc Natl Acad Sci U S A. 2004. PMID: 14688411 Free PMC article.
-
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334-9. doi: 10.1073/pnas.061509598. Proc Natl Acad Sci U S A. 2001. PMID: 11248079 Free PMC article.
-
Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.JAMA. 1995 Mar 22-29;273(12):942-7. JAMA. 1995. PMID: 7884953
-
Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease.J Clin Psychiatry. 1996;57 Suppl 14:9-13. J Clin Psychiatry. 1996. PMID: 9024331 Review.
-
Early detection of Alzheimer's disease using neuroimaging.Exp Gerontol. 2007 Jan-Feb;42(1-2):129-38. doi: 10.1016/j.exger.2006.05.016. Epub 2006 Jul 12. Exp Gerontol. 2007. PMID: 16839732 Review.
Cited by
-
Arterial spin labeling MRI: an emerging biomarker for Alzheimer's disease and other neurodegenerative conditions.Curr Opin Neurol. 2012 Aug;25(4):421-8. doi: 10.1097/WCO.0b013e328354ff0a. Curr Opin Neurol. 2012. PMID: 22610458 Free PMC article.
-
CREB regulates the expression of neuronal glucose transporter 3: a possible mechanism related to impaired brain glucose uptake in Alzheimer's disease.Nucleic Acids Res. 2013 Mar 1;41(5):3240-56. doi: 10.1093/nar/gks1227. Epub 2013 Jan 22. Nucleic Acids Res. 2013. PMID: 23341039 Free PMC article.
-
Characterizing healthy samples for studies of human cognitive aging.Front Aging Neurosci. 2012 Sep 12;4:23. doi: 10.3389/fnagi.2012.00023. eCollection 2012. Front Aging Neurosci. 2012. PMID: 22988440 Free PMC article.
-
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.JAMA Neurol. 2015 Mar;72(3):316-24. doi: 10.1001/jamaneurol.2014.3314. JAMA Neurol. 2015. PMID: 25580592 Free PMC article.
-
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study.Lancet Neurol. 2012 Dec;11(12):1048-56. doi: 10.1016/S1474-4422(12)70228-4. Epub 2012 Nov 6. Lancet Neurol. 2012. PMID: 23137948 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical